Home › Respiratory Distress Syndrome › Florida › Gainesville
Respiratory Distress Syndrome clinical trials in Gainesville, FL
5 studies for Respiratory Distress Syndrome are looking for participants at sites in and around Gainesville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
RecruitingPhase 3
- Research Site, Gainesville
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
RecruitingPhase 2
- North Florida / South Georgia Veterans Health System, Gainesville
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
RecruitingPhase 2
- North Florida / South Georgia Veterans Health System, Gainesville
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
RecruitingPhase 2
- North Florida / South Georgia Veterans Health System, Gainesville
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
RecruitingPhase 2
- North Florida / South Georgia Veterans Health System, Gainesville
Respiratory Distress Syndrome trials in other cities
- Houston, TX11 studies
- New York City, NY10 studies
- West Jordan, UT9 studies
- Boston, MA8 studies
- Durham, NC8 studies
- Denver, CO8 studies
- Birmingham, AL7 studies
- Charlottesville, VA7 studies
- Rochester, MN7 studies
- Evanston, IL7 studies
- Oklahoma City, OK7 studies
- Seattle, WA7 studies
Other studies in Gainesville
- Heart Failure13 studies
- Type 1 Diabetes12 studies
- Breast Cancer12 studies
- Parkinson's Disease12 studies
- Non-Small Cell Lung Cancer10 studies
- Cancer (all types)9 studies
- Colorectal Cancer9 studies
- Lung Cancer9 studies
- Cardiovascular Disease9 studies
- Mild Cognitive Impairment8 studies
- Acute Myeloid Leukemia8 studies
- Prostate Cancer8 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.